- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| ENLIVEN THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| Mi | H.C. Wainwright reiterates Enliven Therapeutics stock rating on Terns deal details | 3 | Investing.com | ||
| 26.03. | Enliven Therapeutics stock price target raised to $56 by H.C. Wainwright | 1 | Investing.com | ||
| 26.03. | Enliven Therapeutics (ELVN) Soars to 5-Year High as Analysts 'Upbeat' | 4 | Insider Monkey | ||
| 25.03. | Clear Street reiterates Enliven Therapeutics stock Buy on CML opportunity | 2 | Investing.com | ||
| 24.03. | Mizuho hebt Kursziel für Enliven Therapeutics nach CML-Daten auf 45 US-Dollar an | 4 | Investing.com Deutsch | ||
| 24.03. | Mizuho raises Enliven Therapeutics price target to $45 on CML data | 5 | Investing.com | ||
| 03.03. | Enliven Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 03.03. | Enliven Therapeutics: Q4 Earnings Insights | 1 | Benzinga.com | ||
| 03.03. | Enliven Therapeutics, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 03.03. | Enliven Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 08.01. | Enliven Therapeutics Early Leukemia Drug Results Impress, Stock Soars | 2 | Benzinga.com | ||
| 08.01. | Enliven Therapeutics meldet positive Phase-1b-Daten für CML-Medikament ELVN-001 | 9 | Investing.com Deutsch | ||
| 08.01. | Enliven reports positive initial phase 1b data for ELVN-001 in CML | 2 | Investing.com | ||
| 08.01. | Enliven Therapeutics, Inc.: Enliven Reports Positive Initial Phase 1b Data for ELVN-001 in CML and Outlines 2026 Clinical Milestones | 298 | PR Newswire | Cumulative major molecular response (MMR) rate of 69% by 24 weeks, with 53% of patients achieving MMR by 24 weeks in ongoing randomized Phase 1b cohorts
ELVN-001... ► Artikel lesen | |
| 07.01. | Enliven Therapeutics beruft Scott Garland vor entscheidender CML-Studie in den Verwaltungsrat | 1 | Investing.com Deutsch | ||
| 07.01. | Scott Garland joins Enliven Therapeutics board as company prepares for CML trial | 1 | Investing.com | ||
| 07.01. | Enliven Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 16.12.25 | Enliven Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| 11.12.25 | Enliven Therapeutics appoints Rick Fair as new CEO | 1 | Investing.com | ||
| 11.12.25 | Enliven Therapeutics, Inc.: Enliven Therapeutics Announces New CEO to Drive Next Phase of Development | 348 | PR Newswire | Rick Fair, a seasoned executive with deep experience developing and commercializing hematology products, joins Enliven as Chief Executive Officer
Co-Founder Sam... ► Artikel lesen |
1 2 Weiter >>
27 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VALNEVA | 2,620 | -3,68 % | Valneva unter massivem Druck: Warum Insider bereits still und leise verkaufen - Was Sie jetzt noch wissen müssen | ||
| BIOFRONTERA | 2,610 | +1,95 % | BIOFRONTERA AG im Abwärtsmodus - ruhige Einordnung | ||
| CRISPR THERAPEUTICS | 44,095 | -0,49 % | CRISPR Therapeutics-Aktie: Milliarden mit Gentherapie CASGEVY? | CRISPR Therapeutics vollzieht den Übergang von einem reinen Forschungsunternehmen zu einem kommerziellen Biotechnologieanbieter. Mit ersten nennenswerten Umsätzen und einer breiten Pipeline an innovativen... ► Artikel lesen | |
| DENALI THERAPEUTICS | 16,760 | -0,42 % | Denali Therapeutics Inc.: Denali Therapeutics Regains Full Rights to Investigational Therapy DNL593 (PTV:PGRN) for GRN-related Frontotemporal Dementia (FTD-GRN) | Denali plans to continue clinical development of DNL593, which is designed to deliver progranulin to the brain using TransportVehicle technologyResults from ongoing Phase 1/2 study in patients with... ► Artikel lesen | |
| UNIQURE | 13,760 | +1,03 % | uniQure Inc.: uniQure Provides Regulatory Update on AMT-130 for Huntington's Disease | LEXINGTON, Mass. and AMSTERDAM, March 02, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs... ► Artikel lesen | |
| FATE THERAPEUTICS | 0,974 | -4,13 % | Fate Therapeutics, Inc.: Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4) | ||
| VOYAGER THERAPEUTICS | 3,342 | -0,24 % | Voyager Therapeutics, Inc.: Voyager Reports Fourth Quarter and Full Year 2025 Financial and Operating Results | - Transformative year for tau in AD: VY1706 clinical entry and VY7523 clinical data anticipated H2 2026 - - Validating brain-targeted capsids in humans: expect two I.V.-delivered neuro gene therapies... ► Artikel lesen | |
| AGIOS | 28,600 | -0,69 % | Agios Pharmaceuticals, Inc.: Agios Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update | PYRUKYND (mitapivat) worldwide net revenues of $20.0 million in fourth quarter and $54.0 million for full yearAQVESME (mitapivat) for thalassemia now available in U.S. following FDA approvalCompany... ► Artikel lesen | |
| CELLECTIS | 3,014 | -3,46 % | Cellectis Inc.: Monthly information on share capital and company voting rights | ||
| SCILEX | 6,100 | -0,81 % | XFRA NEW INSTRUMENTS AVAILABLE ON 10.02.2026 | The following instruments on XETRA do have their first trading 10.02.2026 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 10.02.2026
Aktien
1 CNE100006V73 Auntea Jenny (Shanghai)... ► Artikel lesen | |
| TECTONIC THERAPEUTIC | 30,230 | +0,27 % | Tectonic Therapeutic Announces Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights | Announced positive topline results from TX45 Phase 1b acute hemodynamic clinical trial in patients with Group 2 Pulmonary Hypertension in Heart Failure with reduced Ejection Fraction ("PH-HFrEF")... ► Artikel lesen | |
| ALLOGENE THERAPEUTICS | 2,825 | +4,24 % | Allogene Therapeutics, Inc.: Allogene Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update | Pivotal, Randomized Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First Line (1L) Consolidation in Large B-Cell Lymphoma (LBCL) Positions Company at the Forefront of MRD-Guided... ► Artikel lesen | |
| NUVATION BIO | 4,580 | +0,88 % | Nuvation Bio stock rating reaffirmed at Buy by Truist Securities | ||
| QIAGEN | 35,030 | -1,14 % | QIAGEN N.V.: Qiagen Announces Form 20-F Annual Report Filing for 2025 Results | QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended... ► Artikel lesen | |
| EVOTEC | 4,526 | -3,21 % | Evotec Aktie: 2 Euro oder 6 Euro - wohin geht es für die Biotech-Aktie? | Nach dem Absturz der Evotec Aktie an die 4-Euro-Marke läuft bei dem Biotech-Titel ein erneuter Versuch einer Bodenbildung. Die zentrale charttechnische Unterstützung hat sich diesmal im Kern bei 3,995/4... ► Artikel lesen |
Das Unternehmen ENLIVEN THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 44,600 Euro und damit +3,99 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ENLIVEN THERAPEUTICS INC finden Sie auf Wallstreet Online.